2021年4月6日 · These findings demonstrate that CTLA-4, PD-1, PDL-1, and TIM-3 were highly expressed in TNBC. Based on these high expression patterns, further studies directed towards combined therapies are warranted in advanced TNBC in future.

2024年1月12日 · We evaluated CD155 and TIGIT expression in TNBC tissues using both immunohistochemistry (IHC) and gene expression profiling. Our experiments, both in vivo and in vitro, provided evidence that inhibiting the CD155/TIGIT pathway reinstates the ability of CD8 + T cells to generate cytokines.

2023年8月11日 · TIM-3 is one of the key immune checkpoint receptors that interact with GAL-9, PtdSer, HMGB1 and CEACAM1. Initially identified on the surface of T helper 1 (Th1) lymphocytes and later on cytotoxic lymphocytes (CTLs), monocytes, macrophages, natural killer cells (NKs), and dendritic cells (DCs), TIM-3 plays a key role in immunoregulation.

因此，我们调查了新辅助化疗（NAC）后局部晚期三阴性乳腺癌（TNBC）患者TILs上各种ICR表达。 使用针对PDL-1，PD-1，TIM-3，LAG-3和CTLA-4的单克隆抗体，对外科标本（n = 61）中的ICR表达进行免疫组织化学检查。

Therefore, we investigated various ICR expressions on TILs in patients with locally advanced triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NAC). Methods: Expressions of ICRs were examined immunohistochemically in surgical specimens (n = 61) using monoclonal antibodies for PDL-1, PD-1, TIM-3, LAG-3, and CTLA-4.

2022年6月10日 · Tumor cells constitutively expressing HIF1α were associated with reduced content of both MHC class II-expressing dendritic cells and CD8+ TIM3− T cells. Moreover, TNBC tumors derived from cells that constitutively express HIF1α were 4 …

2021年4月6日 · Therefore, we investigated various ICR expressions on TILs in patients with locally advanced triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NAC). Methods Expressions of...

2022年1月2日 · Conclusion: Our findings suggest that LAG-3 may become a biomarker in highly malignant breast cancers such as TNBC and HER2BC that can predict the therapeutic efficacy of NAC. Keywords: Immunoadjuvant molecules; LAG-3; OX-40; TIM-3; breast cancer; neoadjuvant chemotherapy; pathological complete response.

2024年11月7日 · In a study of 95 specimens of invasive breast cancer (34% luminal A, 33% luminal B, 20% HER2, and 13% TNBC), TIM3 expression (defined as >1% TIM3+ TILs by a combination of flow cytometry and IHC) was associated with co-expression of LAG3 and trended toward association with PD-L1 positivity (p = 0.0562) [69].

2021年4月6日 · These findings demonstrate that CTLA-4, PD-1, PDL-1, and TIM-3 were highly expressed in TNBC. Based on these high expression patterns, further studies directed towards combined therapies are warranted in advanced TNBC in future.